🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care

RecruitingPhase 2, Phase 3Ages 18 Years - anyAllNational Medical Research Radiological Centre of …
NCT06556550 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Currently, the usual standard of palliative treatment used in patients with diagnosed oligometastatic cancer in accordance with the local clinical recommendations is chemotherapy and/or a symptomatic course of radiation therapy in doses less than ablative ones The aim of the study is to increase the effectiveness of treatment of patients with tumors of various localizations with oligometastases in the bones and internal organs with the help of stereotactic radiation therapy. The method of stereotactic radiation therapy will be applied in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy treatment T1-4, N0-3, M0-1, over 18 years of age at the start of treatment, compared with standard methods of palliative therapy in those same patient models.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Histologically confirmed malignant formation (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64). 2. 0-2 points on the WHO/ECOG scale of assessment of the general condition of the patient. 3. The absence of disease progression after the current line of chemotherapeutic treatment. 4. The number of oligometastases is not more than 3 in one organ, in the presence of a multi-organ lesion. 5. The total number of distant metastases is no more than 5. 6. Life expectancy of more than 6 months for brain metastases (GPA-score) 7. The possibility of SBRT for all distant metastases, in accordance with the criteria specified in the study design. 8. Making decisions on the inclusion of a patient in the study protocol based on the results of an interdisciplinary consultation consisting of an oncologist, a chemotherapist and a radiotherapist. 9. Signed informed consent Exclusion Criteria: 1. 3-4 points on the WHO/ECOG scale of assessment of the general condition of the patient 2. The complete response of all foci to the chemotherapy. 3. Distant metastases only in the brain, without damage to bones and other organs. 4. Brain metastasis of more than 3 cm in one dimension, requiring surgical treatment. 5. Distant metastasis in the brain stem and spinal cord. 6. The size of at least one distant metastasis is more than 5 cm. 7. Previously performed radiation therapy on one of the metastatic foci. 8. Metastatic lesion of the pleura, membranes of the brain or peritoneum. 9. The impossibility of CTT for all distant metastases, in accordance with the criteria specified in the study design. 10. Invasion into great vessels (aorta, carotid arteries, pulmonary arteries, etc.), organs of the digestive tract (esophagus, stomach, intestines), skin. 11. Compression of the spinal cord by distant metastasis according to instrumental studies.
💊

What it tests

  • stereotactic ablative radiation therapy
  • palliative radiation therapy
  • Chemotherapy
📍

Where

1 site
A. Tsyb Medical Radiological Research Center
Obninsk, Russia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy